What the FDA labels say about taking them together
Dipyridamole and regadenoson
Dipyridamole's FDA label of September 16, 2023 names regadenoson in its drug interactions section, and regadenoson's label names dipyridamole too. The regadenoson label: “Dipyridamole may increase the activity of LEXISCAN.”
Check it at the source: the dipyridamole FDA label on DailyMed (effective September 16, 2023, Zydus Pharmaceuticals USA Inc.); the regadenoson FDA label on DailyMed (effective December 21, 2018, Astellas Pharma US, Inc.).
What does the dipyridamole label say about regadenoson?
Dipyridamole label, drug interactionsAdenosinergic agents (e.g., adenosine, regadenoson) Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.
Source: FDA drug label (Dipyridamole), Zydus Pharmaceuticals USA Inc., effective September 16, 2023 (SPL set 004bada0-dbf7-4a94-8792-6833d7eeda2b), via openFDA; the full label on DailyMed
What does the regadenoson label say about dipyridamole?
Regadenoson label, drug interactionsDipyridamole may increase the activity of LEXISCAN.
Source: FDA drug label (LEXISCAN), Astellas Pharma US, Inc., effective December 21, 2018 (SPL set 057289f4-2e18-4c1e-bed4-6c1858e2ef16), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dipyridamole | Regadenoson | |
|---|---|---|
| Labeled for | n/a | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.236 per tablet 75 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once